Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price dropped 1.7% during trading on Friday . The stock traded as low as $31.96 and last traded at $32.00, with a volume of 111,681 shares traded. The stock had previously closed at $32.54.

ALDR has been the topic of several research analyst reports. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 30th. Jefferies Group reaffirmed a “buy” rating and set a $61.00 price target on shares of Alder BioPharmaceuticals in a research note on Thursday, June 9th. Finally, Brean Capital reaffirmed a “positive” rating and set a $45.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday, July 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $44.00.

The firm’s 50 day moving average is $30.22 and its 200 day moving average is $26.24. The stock’s market cap is $1.58 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. During the same quarter last year, the firm earned ($0.46) earnings per share. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $1.14 million. Alder BioPharmaceuticals’s revenue for the quarter was up 112900.0% on a year-over-year basis. On average, analysts expect that Alder BioPharmaceuticals Inc. will post ($2.76) EPS for the current year.

In other news, insider John A. Latham sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $31.19, for a total transaction of $311,900.00. Following the sale, the insider now owns 252,200 shares of the company’s stock, valued at approximately $7,866,118. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jeffrey T. L. Smith sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $31.17, for a total transaction of $93,510.00. Following the sale, the vice president now directly owns 3,000 shares in the company, valued at approximately $93,510. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Alder BioPharmaceuticals stock. Wells Fargo & Company MN boosted its position in Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) by 290.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 269,774 shares of the biopharmaceutical company’s stock after buying an additional 200,707 shares during the period. Wells Fargo & Company MN owned 0.62% of Alder BioPharmaceuticals worth $8,911,000 as of its most recent filing with the SEC.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.